Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

NCT ID: NCT00047229

Last Updated: 2017-11-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 27 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-10-31
• Study Completion Date: 2009-04-30

Brief Summary

RATIONALE: Drugs used in chemotherapy such as doxorubicin use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug.

PURPOSE: Phase II trial to study the effectiveness of combining oblimersen with doxorubicin in treating patients who have locally advanced, recurrent, or metastatic hepatocellular carcinoma (liver cancer).

Detailed Description

OBJECTIVES:

• Determine the maximum tolerated dose of oblimersen and doxorubicin in patients with advanced hepatocellular carcinoma or other incurable solid tumor (closed to accrual as of 11/7/03). (Phase I completed as of 1/16/04.)
• Determine the efficacy of this regimen, in terms of objective response rate, in these patients.
• Determine the toxicity of this regimen in these patients.
• Determine the time to progression, response duration, progression-free survival, median survival, and overall survival rates in patients treated with this regimen.

OUTLINE: This is a dose-escalation, multicenter study. (Phase I completed as of 1/16/04.)

Patients receive oblimersen IV continuously on days 1-7 and doxorubicin IV over 5 minutes on day 5. Treatment repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of oblimersen and doxorubicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients*, including 6 patients with hepatocellular carcinoma (HCC), are treated at the recommended phase II dose. (Phase I completed as of 1/16/04.)

NOTE: *Other solid tumors closed to accrual as of 11/7/03; only accruing HCC patients

PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for the phase I portion of this study within 6 months (phase I completed as of 1/16/04). A total of 30 patients will be accrued for the phase II portion of this study within 10-15 months.

Conditions

Liver Cancer

Keywords

adult primary hepatocellular carcinoma; advanced adult primary liver cancer; localized unresectable adult primary liver cancer; recurrent adult primary liver cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

G3139 in combination with Doxorubicin

Group Type: EXPERIMENTAL

oblimersen sodium

Intervention Type: BIOLOGICAL

doxorubicin hydrochloride

Intervention Type: DRUG

Interventions

oblimersen sodium

Intervention Type: BIOLOGICAL

doxorubicin hydrochloride

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

• Histologically or cytologically confirmed hepatocellular carcinoma (HCC)

• Locally advanced, recurrent, or metastatic
• Not candidates for surgical/radical therapies
• Other solid tumor that is incurable (closed to accrual as of 11/7/03)
• At least 1 unidimensionally measurable lesion

• At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
• Target lesion may not be in a previously irradiated field unless subsequent progression was documented
• No ascites
• No known brain metastases

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2 OR
• Karnofsky 60-100%

Life expectancy

• More than 3 months

Hematopoietic

• WBC at least 2,000/mm^3
• Absolute neutrophil count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3

Hepatic

• Bilirubin no greater than 2.0 mg/dL
• AST no greater than 5 times upper limit of normal (ULN)
• Albumin greater than 3.5 g/dL
• No cirrhosis worse than Childs-Pugh class A

Renal

• Creatinine no greater than 1.25 times ULN OR
• Creatinine clearance at least 50 mL/min

Cardiovascular

• LVEF normal by MUGA
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia

Other

• Good nutritional status
• No encephalopathy
• No other concurrent uncontrolled illness
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study participation
• No prior allergic reactions to compounds of similar chemical or biological composition to oblimersen or doxorubicin
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No more than 1 prior biologic therapy regimen for patients with HCC
• At least 4 weeks since prior biologic therapy

Chemotherapy

• Patients with HCC:

• No prior systemic chemotherapy
• Prior chemotherapy as part of localized chemoembolization therapy may be allowed (no more than 150 mg/m^2 for doxorubicin) if completed at least 8 weeks before study treatment
• All other patients (closed to accrual as of 11/7/03):

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No prior doxorubicin, epirubicin, or other anthracycline

Endocrine therapy

• Not specified

Radiotherapy

• See Disease Characteristics
• At least 4 weeks since prior radiotherapy
• No more than 3,000 cGy to fields including substantial bone marrow

Surgery

• At least 8 weeks since prior surgery
• Prior liver transplant for HCC allowed

Other

• Recovered from all prior therapy
• At least 8 weeks since other locally ablative therapies
• No concurrent commercial or other investigational agents or therapies
• No other concurrent anticancer therapy
• No concurrent combination antiretroviral therapy for HIV-positive patients

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 120 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

University Health Network, Toronto

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jennifer Knox, MD

Role: STUDY_CHAIR

Princess Margaret Hospital, Canada

Locations

British Columbia Cancer Agency - Vancouver Cancer Centre

Vancouver, British Columbia, Canada

London Regional Cancer Program at London Health Sciences Centre

London, Ontario, Canada

Princess Margaret Hospital

Toronto, Ontario, Canada

Countries

Canada

References

Knox JJ, Chen XE, Feld R, Nematollahi M, Cheiken R, Pond G, Zwiebel JA, Gill S, Moore M. A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs. 2008 Apr;26(2):193-4. doi: 10.1007/s10637-007-9104-1. Epub 2007 Dec 4. No abstract available.

Reference Type: RESULT

PMID: 18060598 (View on PubMed)

Knox JJ, Chen E, Feld R, et al.: A phase II trial of oblimersen sodium (G3139) in combination with doxorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5798. [Abstract] J Clin Oncol 24 (Suppl 18): A-14072, 2006.

Reference Type: RESULT

Related Links

https://clinicaltrials.gov/ct2/show/NCT00047229

Clinical trial summary from the National Cancer Institute's PDQ® database

Other Identifiers

CDR0000257565

Identifier Type: REGISTRY

Identifier Source: secondary_id

NCI-5798

Identifier Type: -

Identifier Source: secondary_id

PMH-PHL-011

Identifier Type: -

Identifier Source: org_study_id